Implicated in
Anaplasic large cell lymphoma (ALCL) with t(2;5)(p23;q35) --> NPM1/ALK Disease ALCL are high grade non Hodgkin lymphomas; ALK+ ALCL are ALCL where ALK is involved in a fusion gene; ALK+ ALCL represent 50 to 60 % of ALCL cases (they are CD30+, ALK+;); 70 to 80% of ALK+ ALCL cases bear a t(2;5); the remaining ALK+ ALCL cases bear variant translocations described below and are called "cyto-plasmic ALK+" cases, of which is the t(1;2) TPM3/ ALK, found in 20% of ALK+ ALCL. Prognosis Althouth presenting as a high grade tumour, a 80% five year survival is associated with this anomaly. Cytogenetics Additional anomalies and complex karyotypes are most often found. Hybrid/Mutated gene 5' NPM1 -3' ALK on the der(5). Abnormal protein 680 amino acids, 80 kDa; N-term 116 amino acids from NPM1 fused to the 562 C-term aminoacids of ALK (i.e. composed of the oligomerization domain and the metal binding site of NPM1, and the entire cytoplasmic portion of ALK); no apparent expres-sion of the ALK/NPM1 counterpart. Characteristic localisation both in the cytoplasm and in the nucleus, due to heterooligomerization of NPM-ALK and normal NPM whereas the normal NPM protein is confined to the nucleus; constitutive activation of the catalytic domain of ALK. Oncogenesis Via the kinase function activated by oligomeri-zation of NPM1-ALK mediated by the NPM1 part.
Cytoplasmic ALK+ anaplasic large cell lymphoma
Prognosis Present a favourable prognosis comparable to the one found in t(2;5) ALK+ ALCL. Cytogenetics Either t(X;2)(q11;p23), t(1;2)(q25;p23), inv(2)(p23q35), t(2;3)(p23;q21), t(2;17)(p23;q23), t(2;17)(p23;q25) or t(2;22)(p23;q11.2); hidden translocation is frequently found. Hybrid/Mutated gene 5' MSN, TPM3, ATIC, TFG, CLTC, ALO17 or MYH9 -3' ALK.
Abnormal protein N-term amino acids from the partner gene fused to the 562 C-term amino acids (in the great majority of cases) from ALK (i.e. the entire cytoplasmic portion of ALK with the tyrosine kinase domain); cytoplasmic/membraneous localisation only. Oncogenesis The partner gene seems to provoke the dimerization of the fused-ALK, which should lead to constitutive autophosphorylation and activation of the ALK tyrosine kinase, as for NPM1-ALK (see t(2;5)(p23;q35)).
Inflammatory myofibroblastic tumours with 2p23 rearrangements
Disease Rare soft tissue tumour found in children and young adults about one third to half of inflammatory myofibroblastic tumour cases present with a 2p23 rearrangement involving ALK. Prognosis Good prognosis. Cytogenetics t(1;2)(q25;p23), t(2;2)(p23;q13), t(2;11)(p23;p15), t(2;17)(p23;q23) , or t(2;19)(p23;p13.1) so far. Hybrid/Mutated gene 5' TPM3 in the t(1;2), RANBP2 in the t(2;2), CARS in the t(2;11), 5' CLTC in the t(2;17), or 5' TPM4 in the t(2;19)-3' ALK. Abnormal protein N-term amino acids from the partner gene fused to the 562 C-term amino acids from ALK (i.e. the entire cytoplasmic portion of ALK with the tyrosine kinase domain); homodimerization of the fusion protein is known or suspected. Oncogenesis Fused-ALK is contitutively activated.
To be noted
Note ALK and some of the above ALK partners, or closely related genes, are found implicated both in anaplasic large cell lymphoma and in Inflammatory myofibroblastic tumours; this is a new concept, that 2 different types of tumour may result from the same chromosomal/genes rearrangement. 
Note
Most of the breakpoints occur in the same intron of ALK, whichever partner is involved in the fusion protein.
